{
    "organizations": [],
    "uuid": "5d69ed4e63c1b65916da9a25d8431dd55e2d823d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-theravance-biopharma-and-mylan-ann/brief-theravance-biopharma-and-mylan-announce-fda-acceptance-of-new-drug-application-for-revefenacin-idUSASB0C2QY",
    "ord_in_thread": 0,
    "title": "BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 41 PM / Updated 10 minutes ago BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin Reuters Staff 1 Min Read \nJan 29 (Reuters) - Theravance Biopharma Inc: \n* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE \n* THERAVANCE BIOPHARMA INC - FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF NOVEMBER 13, 2018 \n* THERAVANCE BIOPHARMA - ‍ FDA INDICATED IT DOES NOT CURRENTLY PLAN TO CONVENE AN ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR REVEFENACIN (TD-4208)​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-29T15:38:00.000+02:00",
    "crawled": "2018-01-29T16:04:21.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "biopharma",
        "mylan",
        "announce",
        "fda",
        "acceptance",
        "new",
        "drug",
        "application",
        "revefenacin",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "theravance",
        "biopharma",
        "inc",
        "theravance",
        "biopharma",
        "mylan",
        "announce",
        "fda",
        "acceptance",
        "new",
        "drug",
        "application",
        "revefenacin",
        "adult",
        "chronic",
        "obstructive",
        "pulmonary",
        "disease",
        "theravance",
        "biopharma",
        "inc",
        "fda",
        "assigned",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "target",
        "action",
        "date",
        "november",
        "theravance",
        "biopharma",
        "fda",
        "indicated",
        "currently",
        "plan",
        "convene",
        "advisory",
        "committee",
        "meeting",
        "discus",
        "nda",
        "revefenacin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}